Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | EOSINOPHILS | authKW | 811190 | 10% | 26% | 1345 |
2 | OMALIZUMAB | authKW | 449592 | 2% | 60% | 324 |
3 | ALLERGY | WoSSC | 357585 | 24% | 5% | 3248 |
4 | ORAL TOLERANCE | authKW | 302993 | 2% | 45% | 290 |
5 | ASTHMA | authKW | 295658 | 14% | 7% | 1926 |
6 | SEVERE ASTHMA | authKW | 245532 | 2% | 51% | 207 |
7 | EOTAXIN | authKW | 175164 | 1% | 43% | 174 |
8 | CD23 | authKW | 160839 | 1% | 47% | 148 |
9 | IMMUNOLOGY | WoSSC | 154547 | 51% | 1% | 6864 |
10 | ANTI IGE | authKW | 152612 | 1% | 55% | 120 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Allergy | 357585 | 24% | 5% | 3248 |
2 | Immunology | 154547 | 51% | 1% | 6864 |
3 | Respiratory System | 45492 | 16% | 1% | 2107 |
4 | Critical Care Medicine | 3490 | 3% | 0% | 469 |
5 | Cell Biology | 2047 | 8% | 0% | 1125 |
6 | Medicine, Research & Experimental | 1817 | 6% | 0% | 750 |
7 | Hematology | 701 | 3% | 0% | 409 |
8 | Pharmacology & Pharmacy | 523 | 6% | 0% | 865 |
9 | Biochemistry & Molecular Biology | 327 | 9% | 0% | 1234 |
10 | Pathology | 241 | 2% | 0% | 256 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | MOL TUMOR BIOL | 75461 | 1% | 46% | 71 |
2 | CELLULAR GENE THER IES | 66694 | 1% | 30% | 97 |
3 | ASTHMA GRP | 36076 | 0% | 34% | 46 |
4 | TUMOR VACCINES BIOTECHNOL BRANCH | 29164 | 0% | 47% | 27 |
5 | FI TONE P HLTH | 28009 | 1% | 17% | 73 |
6 | BIOL EVALUAT NIH | 23226 | 0% | 100% | 10 |
7 | LUNG HLTH | 18081 | 0% | 12% | 66 |
8 | SECT NEUROSURG H110 | 16258 | 0% | 100% | 7 |
9 | HERITAGE MED 574 | 15673 | 0% | 75% | 9 |
10 | LEUKOCYTE BIOL SECT | 15627 | 0% | 16% | 42 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 109760 | 5% | 7% | 717 |
2 | INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY | 106663 | 3% | 10% | 444 |
3 | CLINICAL AND EXPERIMENTAL ALLERGY | 71056 | 3% | 8% | 398 |
4 | INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY | 61891 | 2% | 10% | 266 |
5 | ALLERGY | 51986 | 3% | 6% | 378 |
6 | JOURNAL OF IMMUNOLOGY | 35823 | 7% | 2% | 926 |
7 | AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY | 26274 | 2% | 5% | 243 |
8 | AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 20599 | 2% | 3% | 298 |
9 | IMMUNOLOGY | 20305 | 2% | 3% | 281 |
10 | EUROPEAN RESPIRATORY JOURNAL | 15084 | 2% | 3% | 248 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | EOSINOPHILS | 811190 | 10% | 26% | 1345 | Search EOSINOPHILS | Search EOSINOPHILS |
2 | OMALIZUMAB | 449592 | 2% | 60% | 324 | Search OMALIZUMAB | Search OMALIZUMAB |
3 | ORAL TOLERANCE | 302993 | 2% | 45% | 290 | Search ORAL+TOLERANCE | Search ORAL+TOLERANCE |
4 | ASTHMA | 295658 | 14% | 7% | 1926 | Search ASTHMA | Search ASTHMA |
5 | SEVERE ASTHMA | 245532 | 2% | 51% | 207 | Search SEVERE+ASTHMA | Search SEVERE+ASTHMA |
6 | EOTAXIN | 175164 | 1% | 43% | 174 | Search EOTAXIN | Search EOTAXIN |
7 | CD23 | 160839 | 1% | 47% | 148 | Search CD23 | Search CD23 |
8 | ANTI IGE | 152612 | 1% | 55% | 120 | Search ANTI+IGE | Search ANTI+IGE |
9 | IGE | 123211 | 3% | 11% | 473 | Search IGE | Search IGE |
10 | INDUCED SPUTUM | 109355 | 1% | 29% | 165 | Search INDUCED+SPUTUM | Search INDUCED+SPUTUM |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 2 |